The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development

Current Cancer Drug Targets

Volumn 4, Issue 3, 2004, Pages 235-256

  Mitsiades, Constantine S ^a,b   Mitsiades, Nicholas ^a   Koutsilieris, Michael ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BAD; PROTEIN KINASE B; PROTEIN MDM2; S6 KINASE; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HEMATOLOGIC MALIGNANCY; HUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; SOLID TUMOR;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 2342436459     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043333032     Document Type: Review

References (304)

1. Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell 2000, 100, 57-70.
2. Mitsiades, C. S.; Koutsilieris, M. Molecular Biology and Cellular Physiology of Refractoriness to Androgen Ablation Therapy in Advanced Prostate Cancer. Expert Opin. Investig. Drugs 2001, 10, 1099-1115.
3. Staal, S. P. Molecular Cloning of the Akt Oncogene and its Human Homologues Akt1 and Akt2: Amplification of Akt1 in a Primary Human Gastric Adenocarcinoma. Proc. Natl. Acad. Sci. U S A 1987, 84, 5034-5037.
4. Coffer, P. J.; Woodgett, J. R. Molecular Cloning and Characterisation of a Novel Putative Protein-serine Kinase Related to the cAMP-dependent and Protein Kinase C Families. Eur. J. Biochem. 1991, 201, 475-481.
5. Jones, P. F.; Jakubowicz, T.; Pitossi, F. J.; Maurer, F.; Hemmings, B. A. Molecular Cloning and Identification of a Serine/threonine Protein Kinase of the Second-messenger Subfamily. Proc. Natl. Acad. Sci. USA 1991, 88, 4171-4175.
6. Bellacosa, A.; Testa, J. R.; Staal, S. P.; Tsichlis, P. N. A Retroviral Oncogene, Akt, Encoding a Serine-threonine Kinase Containing an SH2-like Region. Science 1991, 254, 274-277.
7. Datta, S. R.; Brunet, A.; Greenberg, M. E. Cellular Survival: A Play in Three Akts. Genes Dev. 1999, 13, 2905-2927.
8. Scheid, M. P.; Woodgett, J. R. PKB/AKT: Functional Insights from Genetic Models. Nat. Rev. Mol. Cell Biol. 2001, 2, 760-768.
9. Alessi, D. R.; Caudwell, F. B.; Andjelkovic, M.; Hemmings, B. A.; Cohen, P. Molecular Basis for the Substrate Specificity of Protein Kinase B; Comparison with MAPKAP Kinase-1 and p70 S6 Kinase. FEBS Lett. 1996, 399, 333-338.
10. Andjelkovic, M.; Alessi, D. R.; Meier, R.; Fernandez, A.; Lamb, N. J.; Frech, M.; Cron, P.; Cohen, P.; Lucocq, J. M.; Hemmings, B. A. Role of Translocation in the Activation and Function of Protein Kinase B. J. Biol. Chem. 1997, 272, 31515-31524.
11. Bellacosa, A.; Chan, T. O.; Ahmed, N. N.; Datta, K.; Malstrom, S.; Stokoe, D.; McCormick, F.; Feng, J.; Tsichlis, P. Akt Activation by Growth Factors is a Multiple-step Process: The Role of the PH Domain. Oncogene 1998, 17, 313-325.
12. Vanhaesebroeck, B.; Alessi, D. R. The PI3K-PDK1 Connection: More Than Just a Road to PKB. Biochem. J. 2000, 346 Pt. 3, 561-576.
13. Stokoe, D.; Stephens, L. R.; Copeland, T.; Gaffney, P. R.; Reese, C. B.; Painter, G. F.; Holmes, A. B.; McCormick, F.; Hawkins, P. T. Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B. Science 1997, 277, 567-570.
14. Alessi, D. R.; James, S. R.; Downes, C. P.; Holmes, A. B.; Gaffney, P. R.; Reese, C. B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent Protein Kinase Which Phosphorylates and Activates Protein Kinase Balpha. Curr. Biol. 1997, 7, 261-269.
15. Toker, A.; Newton, A. C. Akt/protein Kinase B is Regulated by Autophosphorylation at the Hypothetical PDK-2 Site. J. Biol. Chem. 2000, 275, 8271-8274.
16. Laine, J.; Kunstle, G.; Obata, T.; Sha, M.; Noguchi, M. The Protooncogene TCLI is an Akt Kinase Coactivator. Mol. Cell 2000, 6, 395-407.
17. Andjelkovic, M.; Jakubowicz, T.; Cron, P.; Ming, X. F.; Han, J. W.; Hemmings, B. A. Activation and Phosphorylation of a Pleckstrin Homology Domain Containing Protein Kinase (RACPK/PKB) Promoted by Serum and Protein Phosphatase Inhibitors. Proc. Natl. Acad. Sci. USA 1996, 93, 5699-5704.
18. Sato, S.; Fujita, N.; Tsuruo, T. Modulation of Akt Kinase Activity by Binding to Hsp90. Proc. Natl. Acad. Sci. U S A 2000, 97, 10832-10837.
19. Maira, S. M.; Galetic, I.; Brazil, D. P.; Kaech, S.; Ingley, E.; Thelen, M.; Hemmings, B. A. Carboxyl-terminal Modulator Protein (CTMP), A Negative Regulator of PKB/Akt and v-Akt at the Plasma Membrane. Science 2001, 294, 374-380.
20. White, M. F. The IRS-signalling System: A Network of Docking Proteins that Mediate Insulin Action. Mol. Cell Biochem. 1998, 182, 3-11.
21. Yu, J.; Zhang, Y.; McIlroy, J.; Rordorf-Nikolic, T.; Orr, G. A.; Backer, J. M. Regulation of the p85/p110 Phosphatidylinositol 3′-kinase: Stabilization and Inhibition of the p110alpha Catalytic Subunit by the p85 Regulatory Subunit. Mol. Cell Biol. 1998, 18, 1379-1387.
22. Yu, J.; Wjasow, C.; Backer, J. M. Regulation of the p85/p110alpha Phosphatidylinositol 3′-kinase. Distinct Roles for the N-terminal and C-terminal SH2 Domains. J. Biol. Chem. 1998, 273, 30199-30203.
23. Rodriguez-Viciana, P.; Warne, P. H.; Dhand, R.; Vanhaesebroeck, B.; Gout, I.; Fry, M. J.; Waterfield, M. D.; Downward, J. Phosphatidylinositol-3-OH Kinase as a Direct Target of Ras. Nature 1994, 370, 527-532.
24. Kodaki, T.; Woscholski, R.; Hallberg, B.; Rodriguez-Viciana, P.; Downward, J.; Parker, P. J. The Activation of Phosphatidylinositol 3-kinase by Ras. Curr. Biol. 1994, 4, 798-806.
25. Rodriguez-Viciana, P.; Warne, P. H.; Khwaja, A.; Marte, B. M.; Pappin, D.; Das, P.; Waterfield, M. D.; Ridley, A.; Downward, J. Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras. Cell 1997, 89, 457-467.
26. Myers, M. P.; Pass, I.; Batty, I. H.; Van der Kaay, J.; Stolarov, J. P.; Hemmings, B. A.; Wigler, M. H.; Downes, C. P.; Tonks, N. K. The Lipid Pphosphatase Activity of PTEN is Critical for its Tumor Supressor Function. Proc. Natl. Acad. Sci. USA 1998, 95, 13513-13518.
27. Haas-Kogan, D.; Shalev, N.; Wong, M.; Mills, G.; Yount, G.; Stokoe, D. Protein Kinase B (PKB/Akt) Activity is Elevated in Glioblastoma Cells Due to Mutation of the Tumor Suppressor PTEN/MMAC. Curr. Biol. 1998, 8, 1195-1198.
28. Stambolic, V.; Suzuki, A.; de la Pompa, J. L.; Brothers, G. M.; Mirtsos, C.; Sasaki, T.; Ruland, J.; Penninger, J. M.; Siderovski, D. P.; Mak, T. W. Negative Regulation of PKB/Akt-dependent Cell Survival by the Tumor Suppressor PTEN. Cell 1998, 95, 29-39.
29. Wu, X.; Senechal, K.; Neshat, M. S.; Whang, Y. E.; Sawyers, C. L. The PTEN/MMACI Tumor Suppressor Phosphatase Functions as a Negative Regulator of the Phosphoinositide 3-kinase/Akt Pathway. Proc. Natl. Acad. Sci. USA 1998, 95, 15587-15591.
30. Maehama, T.; Dixon, J. E. The Tumor Suppressor, PTEN/ MMACI, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273, 13375-13378.
31. Steck, P. A.; Pershouse, M. A.; Jasser, S. A.; Yung, W. K.; Lin, H.; Ligon, A. H.; Langford, L. A.; Baumgard, M. L.; Hattier, T.; Davis, T.; Frye, C.; Hu, R.; Swedlund, B.; Teng, D. H.; Tavtigian, S. V. Identification of a Candidate Tumour Suppressor Gene, MMACI, at Chromosome 10q23.3 that is Mutated in Multiple Advanced Cancers. Nat. Genet. 1997, 15, 356-362.
32. Li, D. M.; Sun, H. TEPI, Encoded by a Candidate Tumor Suppressor Locus, is a Novel Protein Tyrosine Phosphatase Regulated by Transforming Growth Factor Beta. Cancer Res. 1997, 57, 2124-2129.
33. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S. I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; Bigner, S. H.; Giovanella, B. C. ; Ittmann, M.; Tycko, B.; Hibshoosh, H.; Wigler, M. H.; Parsons, R. PTEN, A Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer. Science 1997, 275, 1943-1947.
34. Gu, H.; Maeda, H.; Moon, J. J.; Lord, J. D.; Yoakim, M.; Nelson, B. H.; Neel, B. G. New Role for Shc in Activation of the Phosphatidylinositol 3-kinase/Akt Pathway. Mol. Cell Biol. 2000, 20, 7109-7120.
35. Tamura, M.; Gu, J.; Matsumoto, K.; Aota, S.; Parsons, R.; Yamada, K. M. Inhibition of Cell Migration, Spreading and Focal Adhesions by Tumor Suppressor PTEN. Science 1998, 280, 1614-1617.
36. Tamura, M.; Gu, J.; Takino, T.; Yamada, K. M. Tumor Suppressor PTEN Inhibition of Cell Invasion, Migration and Growth: Differential Involvement of Focal Adhesion Kinase and p130Cas. Cancer Res. 1999, 59, 442-449.
37. Dufourny, B.; Alblas, J.; van Teeffelen, H. A.; van Schaik, F. M.; van der Burg, B.; Steenbergh, P. H.; Sussenbach, J. S. Mitogenic Signaling of Insulin-like Growth Factor 1 in MCF-7 Human Breast Cancer Cells Requires Phosphatidylinositol 3-kinase and is Independent of Mitogen-activated Protein Kinase. J. Biol. Chem. 1997, 272, 31163-31171.
38. Ahmad, S.; Singh, N.; Glazer, R. I. Role of AKT1 in 17beta-estradiol- and Insulin-like Growth Factor 1 (IGF-I)-dependent Proliferation and Prevention of Apoptosis in MCF-7 Breast Carcinoma Cells. Biochem. Pharmacol. 1999, 58, 425-430.
39. Bartucci, M.; Morelli, C.; Mauro, L.; Ando, S.; Surmacz, E. Differential Insulin-like Growth Factor 1 Receptor Signaling and Function in Estrogen Receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 Breast Cancer Cells. Cancer Res. 2001, 61, 6747-6754.
40. Chan, T. W.; Pollak, M.; Huynh, H. Inhibition of Insulin-like Growth Factor Signaling Pathways in Mammary Gland by Pure Antiestrogen ICI 182,780. Clin. Cancer Res. 2001, 7, 2545-2554.
41. Mitsiades, C. S.; Mitsiades, N.; McMullan, C. J.; Poulaki, V.; Shringarpure, R.; Akiyama, M.; et al. Inhibition of the Insulin-like Growth Factor Receptor-1 Tyrosine Kinase Activity as a Therapeutic Strategy for Multiple Myeloma, Other Hematologic Malignancies and Solid Tumors. Cancer Cell 2004, 5, 221-230.
42. Razzini, G.; Berrie, C. P.; Vignati, S.; Broggini, M.; Mascetta, G.; Brancaccio, A.; Falasca, M. Novel Functional PI 3-kinase Antagonists Inhibit Cell Growth and Tumorigenicity in Human Cancer Cell Lines. FASEB J. 2000, 14, 1179-1187.
43. Liu, B.; Fang, M.; Lu, Y.; Mendelsohn, J.; Fan, Z. Fibroblast Growth Factor and Insulin-like Growth Factor Differentially Modulate the Apoptosis and GI Arrest Induced by Anti-epidermal Growth Factor Receptor Monoclonal Antibody. Oncogene 2001, 20, 1913-1922.
44. Adachi, Y.; Lee, C. T.; Coffee, K.; Yamagata, N.; Ohm, J. E.; Park, K. H.; Dikov, M. M.; Nadaf, S. R.; Arteaga, C. L.; Carbone, D. P. Effects of Genetic Blockade of the Insulin-like Growth Factor Receptor in Human Colon Cancer Cell Lines. Gastroenterology 2002, 123, 1191-1204.
45. Poulaki, V.; Mitsiades, C. S.; Kotoula, V.; Tseleni-Balafouta, S.; Ashkenazi, A.; Koutras, D. A.; Mitsiades, N. Regulation of Apo2L/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Thyroid Carcinoma Cells. Am. J. Pathol. 2002, 161, 643-654.
46. Saito, J.; Kohn, A. D.; Roth, R. A.; Noguchi, Y.; Tatsumo, I.; Hirai, A. ; Suzuki, K.; Kohn, L. D.; Saji, M.; Ringel, M. D. Regulation of FRTL-5 Thyroid Cell Growth by Phosphatidylinositol (OH) 3 Kinase-dependent Akt-mediated Signaling. Thyroid 2001, 11, 339-351.
47. Coulonval, K.; Vandeput, F.; Stein, R. C.; Kozma, S. C.; Lamy, F.; Dumont, J. E. Phosphatidylinositol 3-kinase, Protein Kinase B and Ribosomal S6 Kinases in the Stimulation of Thyroid Epithelial Cell Proliferation by cAMP and Growth Factors in the Presence of Insulin. Biochem. J. 2000, 348 Pt. 2, 351-358.
48. Satyamoorthy, K.; Li, G.; Vaidya, B.; Patel, D.; Herlyn, M. Insulin-like Growth Factor-1 Induces Survival and Growth of Biologically Early Melanoma Cells Through Both the Mitogen-activated Protein Kinase and Beta-catenin Pathways. Cancer Res. 2001, 61, 7318-7324.
49. Yao, Z.; Okabayashi, Y.; Yutsudo, Y.; Kitamura, T.; Ogawa, W.; Kasuga, M. Role of Akt in Growth and Survival of PANC-I Pancreatic Cancer Cells. Pancreas 2002, 24, 42-46.
50. Ge, N. L.; Rudikoff, S. Expression of PTEN in PTEN-deficient Multiple Myeloma Cells Abolishes Tumor Growth In Vivo. Oncogene 2000, 19, 4091-4095.
51. Tu, Y.; Gardner, A.; Lichtenstein, A. The Phosphatidylinositol 3-kinase/AKT Kinase Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and Proliferative Responses. Cancer Res. 2000, 60, 6763-6770.
52. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T. A.; Treon, S. P.; Munshi, N. C.; Richardson, P. G.; Hideshima, T.; Anderson, K. C. Molecular Sequelae of Proteasome Inhibition in Human Multiple Myeloma Cells. Proc. Natl. Acad. Sci. USA 2002, 99, 14374-14379.
53. Mitsiades, C. S.; Mitsiades, N.; Poulaki, V.; Schlossman, R.; Akiyama, M.; Chauhan, D.; Hideshima, T.; Treon, S. P.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C. Activation of NF-kappaB and Upregulation of Intracellular Anti-apoptotic Proteins via the IGF-I/Akt Signaling in Human Multiple Myeloma Cells: Therapeutic Implications. Oncogene 2002, 21, 5673-5683.
54. Walsh, P. T.; Smith, L. M.; O'Connor, R. Insulin-like Growth Factor-1 Activates Akt and Jun N-terminal Kinases (JNKs) in Promoting the Survival of T Lymphocytes. Immunology 2002, 107, 461-471.
55. Jackson, J. G.; Kreisberg, J. I.; Koterba, A. P.; Yee, D.; Brattain, M. G. Phosphorylation and Nuclear Exclusion of the Forkhead Transcription Factor FKHR After Epidermal Growth Factor Treatment in Human Breast Cancer Cells. Oncogene 2000, 19, 4574-4581.
56. Gibson, S.; Tu, S.; Oyer, R.; Anderson, S. M.; Johnson, G. L. Epidermal Growth Factor Protects Epithelial Cells Against Fas-induced Apoptosis. Requirement for Akt Activation. J. Biol. Chem. 1999, 274, 17612-17618.
57. Bianco, C.; Tortora, G.; Bianco, R.; Caputo, R.; Veneziani, B. M.; Damiano, V.; Troiani, T.; Fontanini, G.; Raben, D.; Pepe, S.; Bianco, A. R.; Ciardiello, F. Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor ZD1839 (Iressa). Clin. Cancer. Res. 2002, 8, 3250-3258.
58. Kue, P. F.; Daaka, Y. Essential Role for G Proteins in Prostate Cancer Cell Growth and Signaling. J. Urol. 2000, 164, 2162-2167.
59. Zhuang, L.; Lin, J.; Lu, M. L.; Solomon, K. R.; Freeman, M. R. Cholesterol-rich Lipid Rafts Mediate Akt-regulated Survival in Prostate Cancer Cells. Cancer Res. 2002, 62, 2227-2231.
60. Bunn, P. A., Jr.; Franklin, W. Epidermal Growth Factor Receptor Expression, Signal Pathway, and Inhibitors in Non-small Cell Lung Cancer. Semin. Oncol. 2002, 29, 38-44.
61. Busse, D.; Doughty, R. S.; Ramsey, T. T.; Russell, W. E.; Price, J. O.; Flanagan, W. M.; Shawver, L. K.; Arteaga, C. L. Reversible G(I) Arrest Induced by Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Requires Up-regulation of p27(KIP1) Independent of MAPK Activity. J. Biol. Chem. 2000, 275, 6987-6995.
62. Ng, S. S.; Tsao, M. S.; Nicklee, T.; Hedley, D. W. Effects of the Epidermal Growth Factor Receptor Inhibitor OSI-774, Tarceva, on Downstream Signaling Pathways and Apoptosis in Human Pancreatic Adenocarcinoma. Mol. Cancer Ther. 2002, 1, 777-783.
63. Welm, B. E.; Freeman, K. W.; Chen, M.; Contreras, A.; Spencer, D. M.; Rosen, J. M. Inducible Dimerization of FGFRI: Development of a Mouse Model to Analyze Progressive Transformation of the Mammary Gland. J. Cell Biol. 2002, 157, 703-714.
64. Jang, J. H.; Chung, C. P. A Novel Splice Variant of Fibroblast Growth Factor Receptor 2 in Human Leukemia HL-60 Cells. Blood Cells Mol. Dis. 2002, 29, 133-137.
65. Gerber, H. P.; McMurtrey, A.; Kowalski, J.; Yan, M.; Keyt, B. A.; Dixit, V.; Ferrara, N. Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-kinase/Akt Signal Transduction Pathway. Requirement for Flk-1/KDR Activation. J. Biol. Chem. 1998, 273, 30336-30343.
66. Tran, J.; Rak, J.; Sheehan, C.; Saibil, S. D.; LaCasse, E.; Korneluk, R. G.; Kerbel, R. S. Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells. Biochem. Biophys. Res. Commun. 1999, 264, 781-788.
67. Hideshima, T.; Chauhan, D.; Hayashi, T.; Podar, K.; Akiyama, M.; Gupta, D.; Richardson, P.; Munshi, N.; Anderson, K. C. The Biological Sequelae of Stromal Cell-derived Factor-1alpha in Multiple Myeloma. Mol. Cancer Ther. 2002, 1, 539-544.
68. Koistinen, P.; Siitonen, T.; Mantymaa, P.; Saily, M.; Kinnula, V.; Savolainen, E. R.; Soini, Y. Regulation of the Acute Myeloid Leukemia Cell Line OCI/AML-2 by Endothelial Nitric Oxide Synthase Under the Control of a Vascular Endothelial Growth Factor Signaling System. Leukemia 2001, 15, 1433-1441.
69. Price, D. J.; Miralem, T.; Jiang, S.; Steinberg, R.; Avraham, II. Role of Vascular Endothelial Growth Factor in the Stimulation of Cellular Invasion and Signaling of Breast Cancer Cells. Cell Growth Differ. 2001, 12, 129-135.
70. Bai, R. Y.; Ouyang, T.; Miething, C.; Morris, S. W.; Peschel, C.; Duyster, J. Nucleophosmin-anaplastic Lymphoma Kinase Associated with Anaplastic Large-cell Lymphoma Activates the Phosphatidylinositol 3-kinase/Akt Antiapoptotic Signaling Pathway. Blood 2000, 96, 4319-4327.
71. Slupianek, A.; Nieborowska-Skorska, M.; Hoser, G.; Morrione, A.; Majewski, M.; Xue, L.; Morris, S. W.; Wasik, M. A.; Skorski, T. Role of Phosphatidylinositol 3-kinase-Akt Pathway in Nucleophosmin/anaplastic Lymphoma Kinase-mediated Lymphomagenesis. Cancer Res. 2001, 61, 2194-2199.
72. Dudek, H.; Datta, S. R.; Franke, T. F.; Birnbaum, M. J.; Yao, R.; Cooper, G. M.; Segal, R. A.; Kaplan, D. R.; Greenberg, M. E. Regulation of Neuronal Survival by the Serine-threonine Protein Kinase Akt. Science 1997, 275, 661-665.
73. Li, J.; Simpson, L.; Takahashi, M.; Miliaresis, C.; Myers, M. P.; Tonks, N.; Parsons, R. The PTEN/MMACI Tumor Suppressor Induces Cell Death that is Rescued by the AKT/protein Kinase B Oncogene. Cancer Res. 1998, 58, 5667-5672.
74. Romashkova, J. A.; Makarov, S. S. NF-kappaB is a Target of AKT in Anti-apoptotic PDGF Signalling. Nature 1999, 401, 86-90.
75. Kane, L. P.; Shapiro, V. S.; Stokoe, D.; Weiss, A. Induction of NF-kappaB by the Akt/PKB Kinase. Curr. Biol. 1999, 9, 601-604.
76. Ozes, O. N.; Mayo, L. D.; Gustin, J. A.; Pfeffer, S. R.; Pfeffer, L. M.; Donner, D. B. NF-kappaB Activation by Tumour Necrosis Factor Requires the Akt Serine-threonine Kinase. Nature 1999, 401, 82-85.
77. Mayo, L. D.; Donner, D. B. A Phosphatidylinositol 3-kinase/Akt Pathway Promotes Translocation of Mdm2 from the Cytoplasm to the Nucleus. Proc. Natl. Acad. Sci. USA 2001, 98, 11598-11603.
78. Zhou, B. P.; Liao, Y.; Xia, W.; Zou, Y.; Spohn, B.; Hung, M. C. HER-2/ neu Induces p53 Ubiquitination Via Akt-mediated MDM2 Phosphorylation. Nat. Cell Biol. 2001, 3, 973-982.
79. Stambolic, V.; MacPherson, D.; Sas, D.; Lin, Y.; Snow, B.; Jang, Y.; Benchimol, S.; Mak, T. W. Regulation of PTEN Transcription by p53. Mol. Cell 2001, 8, 317-325.
80. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of Cell Death Protease Caspase-9 by Phosphorylation. Science 1998, 282, 1318-1321.
81. Biggs, W. H., 3rd; Meisenhelder, J.; Hunter, T.; Cavenee, W. K.; Arden, K. C. Protein Kinase B/Akt-mediated Phosphorylation Promotes Nuclear Exclusion of the Winged Helix Transcription Factor FKHRI. Proc. Natl. Acad. Sci. USA 1999, 96, 7421-7426.
82. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor. Cell 1999, 96, 857-868.
83. del Peso, L.; Gonzalez, V. M.; Hernandez, R.; Barr, F. G.; Nunez, G. Regulation of the Forkhead Transcription Factor FKHR, but not the PAX3-FKHR Fusion Protein, by the Serine/threonine Kinase Akt. Oncogene 1999, 18, 7328-7333.
84. Kashii, Y.; Uchida, M.; Kirito, K.; Tanaka, M.; Nishijima, K.; Toshima, M.; Ando, T.; Koizumi, K.; Endoh, T.; Sawada, K.; Momoi, M.; Miura, Y.; Ozawa, K.; Komatsu, N. A Member of Forkhead Family Transcription Factor, FKHRLI, is One of the Downstream Molecules of Phosphatidylinositol 3-kinase-Akt Activation Pathway in Erythropoietin Signal Transduction. Blood 2000, 96, 941-949.
85. Kops, G. J.; Burgering, B. M. Forkhead Transcription Factors are Targets of Signalling by the Proto-oncogene PKB (C-AKT). J. Anat. 2000, 197 Pt. 4, 571-574.
86. Nakamura, N.; Ramaswamy, S.; Vazquez, F.; Signoretti, S.; Loda, M.; Sellers, W. R. Forkhead Transcription Factors are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN. Mol. Cell Biol. 2000, 20, 8969-8982.
87. Uddin, S.; Kottegoda, S.; Stigger, D.; Platanias, L. C.; Wickrema, A. Activation of the Akt/FKHRLI Pathway Mediates the Antiapoptotic Effects of Erythropoietin in Primary Human Erythroid Progenitors. Biochem. Biophys. Res. Commun. 2000, 275, 16-19.
88. Brownawell, A. M.; Kops, G. J.; Macara, I. G.; Burgering, B. M. Inhibition of Nuclear Import by Protein Kinase B (Akt) Regulates the Subcellular Distribution and Activity of the Forkhead Transcription Factor AFX. Mol. Cell. Biol. 2001, 21, 3534-3546.
89. Linseman, D. A.; Phelps, R. A.; Bouchard, R. J.; Le, S. S.; Laessig, T. A.; McClure, M. L.; Heidenreich, K. A. Insulin-like Growth Factor-1 Bloeks Bcl-2 Interacting Mediator of Cell Death (Bim) Induction and Intrinsic Death Signaling in Cerebellar Granule Neurons. J. Neurosci. 2002, 22, 9287-9297.
90. Ramaswamy, S.; Nakamura, N.; Sansal, I.; Bergeron, L.; Sellers, W. R. A Novel Mechanism of Gene Regulation and Tumor Suppression by the Transcription Factor FKHR. Cancer Cell 2002, 2, 81-91.
91. Li, P.; Lee, H.; Guo, S.; Unterman, T. G.; Jenster, G.; Bai, W. AKT-independent Protection of Prostate Cancer Cells from Apoptosis Mediated through Complex Formation Between the Androgen Receptor and FKHR. Mol. Cell Biol. 2003, 23, 104-118.
92. Wen, Y.; Hu, M. C.; Makino, K.; Spohn, B.; Bartholomeusz, G.; Yan, D. H. ; Hung, M. C. HER-2/neu Promotes Androgen-independent Survival and Growth of Prostate Cancer Cells through the Akt Pathway. Cancer Res. 2000, 60, 6841-6845.
93. Sharma, M.; Chuang, W. W.; Sun, Z. Phosphatidylinositol 3-kinase/Akt Stimulates Androgen Pathway through GSK3beta Inhibition and Nuclear Beta-catenin Accumulation. J. Biol. Chem. 2002, 277, 30935-30941.
94. Zha, J.; Harada, H.; Yang, E.; Jockel, J.; Korsmeyer, S. J. Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 not BCL-X(L). Cell 1996, 87, 619-628.
95. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt Phosphorylation of BAD Couples Survival Signals to the Cell-intrinsic Death Machinery. Cell 1997, 91, 231-241.
96. del Peso, L.; Gonzalez-Garcia, M.; Page, C.; Herrera, R.; Nunez, G. Interleukin-3-induced Phosphorylation of BAD through the Protein Kinase Akt. Science 1997, 278, 687-689.
97. Downward, J. Mechanisms and Consequences of Activation of Protein Kinase B/Akt. Curr. Opin. Cell Biol. 1998, 10, 262-267.
98. Serrano, M.; Lin, A. W.; McCurrach, M. E.; Beach, D.; Lowe, S. W. Oncogenic Ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and pI6lNK4a. Cell 1997, 88, 593-602.
99. Lin, A. W.; Barradas, M.; Stone, J. C.; van Aelst, L.; Serrano, M.; Lowe, S. W. Premature Senescence Involving p53 and p16 is Activated in Response to Constitutive MEK/MAPK Mitogenic Signaling. Genes Dev. 1998, 12, 3008-3019.
100. Diehl, J. A.; Cheng, M.; Roussel, M. F.; Sherr, C. J. Glycogen Synthase Kinase-3beta Regulates Cyclin D1 Proteolysis and Subcellular Localization. Genes Dev. 1998, 12, 3499-3511.
101. Dijkers, P. F.; Birkenkamp, K. U.; Lam, E. W.; Thomas, N. S.; Lammers, J. W.; Koenderman, L.; Coffer, P. J. FKHR-LI can act as a Critical Effector of Cell Death Induced by Cytokine Withdrawal: Protein Kinase B-enhanced Cell Survival through Maintenance of Mitochondrial Integrity. J. Cell Biol. 2002, 156, 531-542.
102. Medema, R. H.; Kops, G. J.; Bos, J. L.; Burgering, B. M. AFX-like Forkhead Transcription Factors Mediate Cell-cycle Regulation by Ras and PKB through p27kip1. Nature 2000, 404, 782-787.
103. Lawlor, M. A.; Rotwein, P. Insulin-like Growth Factor-mediated Muscle Cell Survival: Central Roles for Akt and Cyclin-dependent Kinase Inhibitor p21. Mol. Cell Biol. 2000, 20, 8983-8995.
104. Rossig, L.; Badorff, C.; Holzmann, Y.; Zeiher, A. M.; Dimmeler, S. Glycogen Synthase Kinase-3 Couples AKT-dependent Signaling to the Regulation of p21Cip1 Degradation. J. Biol. Chem. 2002, 277, 9684-9689.
105. Rossig, L.; Jadidi, A. S.; Urbich, C.; Badorff, C.; Zeiher, A. M.; Dimmeler, S. Akt-dependent Phosphorylation of p21(Cip1) Regulates PCNA Binding and Proliferation of Endothelial Cells. Mol. Cell Biol. 2001, 21, 5644-5657.
106. Schmelzle, T.; Hall, M. N. TOR, A Central Controller of Cell Growth. Cell 2000, 103, 253-262.
107. Nave, B. T.; Ouwens, M.; Withers, D. J.; Alessi, D. R.; Shepherd, P. R. Mammalian Target of Rapamycin is a Direct Target for Protein Kinase B: Identification of a Convergence Point for Opposing Effects of Insulin and Amino-acid Deficiency on Protein Translation. Biochem. J. 1999, 344 Pt. 2, 427-431.
108. Sekulic, A.; Hudson, C. C.; Homme, J. L.; Yin, P.; Otterness, D. M.; Karnitz, L. M.; Abraham, R. T. A Direct Linkage Between the Phosphoinositide 3-kinase-AKT Signaling Pathway and the Mammalian Target of Rapamycin in Mitogen-stimulated and Transformed Cells. Cancer Res. 2000, 60, 3504-3513.
109. Muise-Helmericks, R. C.; Grimes, H. L.; Bellacosa, A.; Malstrom, S. E.; Tsichlis, P. N.; Rosen, N. Cyclin D Expression is Controlled Post-transcriptionally via a Phosphatidylinositol 3-kinase/Akt-dependent Pathway. J. Biol. Chem. 1998, 273, 29864-29872.
110. D'Amico, M.; Hulit, J.; Amanatullah, D. F.; Zafonte, B. T.; Albanese, C. ; Bouzahzah, B.; Fu, M.; Augenlicht, L. H.; Donchower, L. A.; Takemaru, K.; Moon, R. T.; Davis, R.; Lisanti, M. P.; Shutman, M.; Zhurinsky, J.; Ben-Ze'ev, A.; Troussard, A. A.; Dedhar, S.; Pestell, R. G. The Integrin-linked Kinase Regulates the Cyclin D1 Gene through Glycogen Synthase Kinase 3beta and cAMP-responsive Element-binding Protein-dependent Pathways. J. Biol. Chem. 2000, 275, 32649-32657.
111. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K. L. TSC2 is Phosphorylated and Inhibited by Akt and Suppresses mTOR Signalling. Nat. Cell Biol. 2002, 4, 648-657.
112. Embi, N.; Rylatt, D. B.; Cohen, P. Glycogen Synthase Kinase-3 from Rabbit Skeletal Muscle. Separation from Cyclic-AMP-dependent Protein Kinase and Phosphorylase Kinase. Eur. J. Biochem. 1980, 107, 519-527.
113. Cross, D. A.; Alessi, D. R.; Cohen, P.; Andjelkovich, M.; Hemmings, B. A. Inhibition of Glycogen Synthase Kinase-3 by Insulin Mediated by Protein Kinase B. Nature 1995, 378, 785-789.
114. van Weeren, P. C.; de Bruyn, K. M.; de Vries-Smits, A. M.; van Lint, J.; Burgering, B. M. Essential Role for Protein Kinase B (PKB) in Insulin-induced Glycogen Synthase Kinase 3 Inactivation. Characterization of Dominant-negative Mutant of PKB. J. Biol. Chem. 1998, 273, 13150-13156.
115. Ferkey, D. M.; Kimelman, D. GSK-3: New Thoughts on an Old Enzyme. Dev. Biol. 2000, 225, 471-479.
116. Kim, L.; Kimmel, A. R. GSK3, A Master Switch Regulating Celllate Specification and Tumorigenesis. Curr. Opin. Genet. Dev. 2000, 10, 508-514.
117. Shtutman, M.; Zhurinsky, J.; Simcha, I.; Albanese, C.; D'Amico, M.; Pestell, R.; Ben-Ze'ev, A. The Cyclin D1 Gene is a Target of the Beta-catenin/LEF-I Pathway. Proc. Natl. Acad. Sci. USA 1999, 96, 5522-5527.
118. Aberle, H.; Bauer, A.; Stappert, J.; Kispert, A.; Kemler, R. Beta-catenin is a Target for the Ubiquitin-proteasome Pathway. Embo J. 1997, 16, 3797-3804.
119. Lin, S. Y.; Xia, W.; Wang, J. C.; Kwong, K. Y.; Spohn, B.; Wen, Y.; Pestell, R. G.; Hung, M. C. Beta-catenin, A Novel Prognostic Marker for Breast Cancer: Its Roles in Cyclin D1 Expression and Cancer Progression. Proc. Natl. Acad. Sci. USA 2000, 97, 4262-4266.
120. Morin, P. J.; Sparks, A. B.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K. W. Activation of Beta-catenin-Tcf Signaling in Colon Cancer by Mutations in Beta-catenin or APC. Science 1997, 275, 1787-1790.
121. de La Coste, A.; Romagnolo, B.; Billuart, P.; Renard, C. A.; Buendia, M. A.; Soubrane, O.; Fabre, M.; Chelly, J.; Beldjord, C.; Kahn, A.; Perret, C. Somatic Mutations of the Beta-catenin Gene are Frequent in Mouse and Human Hepatocellular Carcinomas. Proc. Natl. Acad. Sci. USA 1998, 95, 8847-8851.
122. Satoh, S.; Daigo, Y.; Furukawa, Y.; Kato, T.; Miwa, N.; Nishiwaki, T.; Kawasoe, T.; Ishiguro, H.; Fujita, M.; Tokino, T.; Sasaki, Y.; Imaoka, S.; Murata, M.; Shimano, T.; Yamaoka, Y.; Nakamura, Y. AXINI Mutations in Hepatocellular Carcinomas and Growth Suppression in Cancer Cells by Virus-mediated Transfer of AXINI. Nat. Genet. 2000, 24, 245-250.
123. Polakis, P. The Adenomatous Polyposis Coli (APC) Tumor Suppressor. Biochim. Biophys. Acta 1997, 1332, F127-147.
124. Fukumoto, S.; Hsieh, C. M.; Maemura, K.; Layne, M. D.; Yet, S. F.; Lee, K. H., Matsui, T.; Rosenzweig, A.; Taylor, W. G.; Rubin, J. S.; Perrella, M. A. ; Lee, M. E. Akt Participation in the Wnt Signaling Pathway through Dishevelled. J. Biol. Chem. 2001, 276, 17479-17483.
125. Warburg, O.; Posener, K.; Negelein, E. On the Metabolism of Cancer Cells. Biochem. Z. 1924, 152.
126. Dang, C. V.; Semenza, G. L. Oncogenic Alterations of Metabolism. Trends Biochem. Sci. 1999, 24, 68-72.
127. Ziegler, A.; von Kienlin, M.; Decorps, M.; Remy, C. High Glycolytic Activity in Rat Glioma Demonstrated In Vivo by Correlation Peak IH Magnetic Resonance Imaging. Cancer Res. 2001, 61, 5595-5600.
128. Cuezva, J. M.; Krajewska, M.; de Heredia, M. L.; Krajewski, S.; Santamaria, G.; Kim, H.; Zapata, J. M.; Marusawa, H.; Chamorro, M.; Reed, J. C. The Bioenergetic Signature of Cancer: A Marker of Tumor Progression. Cancer Res. 2002, 62, 6674-6681.
129. Bares, R.; Klever, P.; Hauptmann, S.; Hellwig, D.; Fass, J.; Cremerius, U.; Schumpelick, V.; Mittermayer, C.; Bull, U. F-18 Fluorodeoxyglucose PET In Vivo Evaluation of Pancreatic Glucose Metabolism for Detection of Pancreatic Cancer. Radiology 1994, 192, 79-86.
130. Conti, P. S.; Lilien, D. L.; Hawley, K.; Keppler, J.; Grafton, S. T.; Bading, J. R. PET and [18F]-FDG in Oncology: A Clinical Update. Nucl. Med. Biol. 1996, 23, 717-735.
131. Di Chiro, G.; DeLaPaz, R. L.; Brooks, R. A.; Sokoloff, L.; Kornblith, P. L.; Smith, B. H.; Patronas, N. J.; Kufta, C. V.; Kessler, R. M.; Johnston, G. S.; Manning, R. G.; Wolf, A. P. Glucose Utilization of Cerebral Gliomas Measured by [18F] Fluorodeoxyglucose and Positron Emission Tomography. Neurology 1982, 32, 1323-1329.
132. Yonekura, Y.; Benua, R. S.; Brill, A. B.; Som, P.; Yeh, S. D.; Kemeny, N. E.; Fowler, J. S.; MacGregor, R. R.; Stamm, R.; Christman, D. R.; Wolf, A. P. Increased Accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in Liver Metastases from Colon Carcinoma. J. Nucl. Med. 1982, 23, 1133-1137.
133. Walenta, S.; Wetterling, M.; Lehrke, M.; Schwickert, G.; Sundfor, K.; Rofstad, E. K.; Mueller-Klieser, W. High Lactate Levels Predict Likelihood of Metastases, Tumor Recurrence, and Restricted Patient Survival in Human Cervical Cancers. Cancer Res. 2000, 60, 916-921.
134. Walenta, S.; Salameh, A.; Lyng, H.; Evensen, J. F.; Mitze, M.; Rofstad, E. K.; Mueller-Klieser, W. Correlation of High Lactate Levels in Head and Neck Tumors with Incidence of Metastasis. Am. J. Pathol. 1997, 150, 409-415.
135. Noguchi, Y.; Saito, A.; Miyagi, Y.; Yamanaka, S.; Marat, D.; Doi, C.; Yoshikawa, T.; Tsuburaya, A.; Ito, T.; Satoh, S. Suppression of Facilitative Glucose Transporter 1 mRNA can Suppress Tumor Growth. Cancer Lett. 2000, 154, 175-182.
136. Yamamoto, T.; Seino, Y.; Fukumoto, H.; Koh, G.; Yano, H.; Inagaki, N.; Yamada, Y.; Inoue, K.; Manabe, T.; Imura, H. Overexpression of Facilitative Glucose Transporter Genes in Human Cancer. Biochem. Biophys. Res. Commun. 1990, 170, 223-230.
137. Mathupala, S. P.; Heese, C.; Pedersen, P. L. Glucose Catabolism in Cancer Cells. The Type 11 Hexokinase Promoter Contains Functionally Active Response Elements for the Tumor Suppressor p53. J. Biol. Chem. 1997, 272, 22776-22780.
138. Aloj, L.; Caraco, C.; Jagoda, E.; Eckelman, W. C.; Neumann, R. D. Glut-1 and Hexokinase Expression: Relationship with 2-fluoro-2-deoxy-D-glucose Uptake in A431 and T47D Cells in Culture. Cancer Res. 1999, 59, 4709-4714.
139. Mathupala, S. P.; Rempel, A.; Pedersen, P. L. Aberrant Glycolytic Metabolism of Cancer Cells: A Remarkable Coordination of Genetic, Transcriptional, Post-translational and Mutational Events that lead to a Critical Role for Type 11 Hexokinase. J. Bioenerg. Biomembr. 1997, 29, 339-343.
140. Hajduch, E.; Heyes, R. R.; Watt, P. W.; Hundal, H. S. Lactate Transport in Rat Adipocytes: Identification of Monocarboxylate Transporter 1 (MCTI) and its Modulation During Streptozotocin-induced Diabetes. FEBS Lett. 2000, 479, 89-92.
141. Hue, L.; Rousseau, G. G. Fructose 2,6-bisphosphate and the Control of Glycolysis by Growth Factors, Tumor Promoters and Oncogenes. Adv. Enzyme Regul. 1993, 33, 97-110.
142. Hennipman, A.; van Oirschot, B. A.; Smits, J.; Rijksen, G.; Staal, G. E. Glycolytic Enzyme Activities in Breast Cancer Metastases. Tumour Biol. 1988, 9, 241-248.
143. Hennipman, A.; van Oirschot, B. A.; Smits, J.; Rijksen, G.; Staal, G. E. Heterogeneity of Glycolytic Enzyme Activity and Isozyme Composition of Pyruvate Kinase in Breast Cancer. Tumour Biol. 1988, 9, 178-189.
144. Hennipman, A.; Smits, J.; van Oirschot, B.; van Houwelingen, J. C.; Rijksen, G.; Neyt, J. P.; Van Unnik, J. A.; Staal, G. E. Glycolytic Enzymes in Breast Cancer. Benign Breast Disease and Normal Breast Tissue. Tumour Biol. 1987, 8, 251-263.
145. Sanchez-Martinez, C.; Estevez, A. M.; Aragon, J. J. Phosphofructokinase C Isozyme from Ascites Tumor Cells: Cloning, Expression and Properties. Biochem. Biophys. Res. Commun. 2000, 271, 635-640.
146. Denis, C.; Paris, H.; Murat, J. C. Hormonal Control of Fructose 2,6-bisphosphate Concentration in the HT29 Human Colon Adenocarcinoma Cell Line. Alpha 2-Adrenergic Agonists Counteract Effect of Vasoactive Intestinal Peptide. Biochem. J. 1986, 239, 531-536.
147. Mojena, M.; Bosca, L.; Hue, L. Effect of Glutamine on Fructose 2,6-bisphosphate and on Glucose Metabolism in HeLa Cells and in Chick-embryo Fibroblasts. Biochem. J. 1985, 232, 521-527.
148. Nissler, K.; Petermann, H.; Wenz, I.; Brox, D. Fructose 2,6-bisphosphate Metabolism in Ehrlich Ascites Tumour Cells. J. Cancer Res. Clin. Oncol. 1995, 121, 739-745.
149. Miralpeix, M.; Azcon-Bieto, J.; Bartrons, R.; Argiles, J. M. The Impairment of Respiration by Glycolysis in the Lewis Lung Carcinoma. Cancer Lett. 1990, 50, 173-178.
150. Chesney, J.; Mitchell, R.; Benigni, F.; Bacher, M.; Spiegel, L.; Al-Abed, Y.; Han, J. H.; Metz, C.; Bucala, R. An Inducible Gene Product for 6-phosphofructo-2-kinase with an AU-rich Instability Element: Role in Tumor Cell Glycolysis and the Warburg Effect. Proc. Natl. Acad. Sci. USA 1999, 96, 3047-3052.
151. Van Schaftingen, E.; Jett, M. F.; Hue, L.; Hers, H. G. Control of liver 6-phosphofructokinase by Fructose 2,6-bisphosphate and Other Effectors. Proc. Natl. Acad. Sci. USA 1981, 78, 3483-3486.
152. Manzano, A.; Perez, J. X.; Nadal, M.; Estivill, X.; Lange, A.; Bartrons, R. Cloning, Expression and Chromosomal Localization of a Human Testis 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Gene. Gene 1999, 229, 83-89.
153. Heine-Suner, D.; Diaz-Guillen, M. A.; Lange, A. J.; Rodriguez de Cordoba, S. Sequence and Structure of the Human 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Heart Isoform Gene (PFKFB2). Eur. J. Biochem. 1998, 234, 103-110.
154. Lange, A. J.; Pilkis, S. J. Sequence of Human Liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Nucleic Acids Res. 1990, 18, 3652.
155. Fernandez de Mattos, S.; de los Pinos, E. E.; Joaquin, M.; Tauler, A. Activation of Phosphatidylinositol 3-kinase is Required for Transcriptional Activity of F-type 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: Assessment of the Role of Protein Kinase B and p70 S6 Kinase. Biochem. J. 2000, 349, 59-65.
156. Perez, J. X.; Roig, T.; Manzano, A.; Dalmau, M.; Boada, J.; Ventura, F.; Rosa, J. L.; Bermudez, J.; Bartrons, R. Overexpression of Fructose 2,6-bisphosphatase Decreases Glycolysis and Delays Cell Cycle Progression. Am. J. Physiol. Cell Physiol. 2000, 279, C1359-1365.
157. Bosca, L.; Mojena, M.; Ghysdael, J.; Rousseau, G. G.; Hue, L. Expression of the v-src or v-fps Oncogene Increases Fructose 2,6-bisphosphate in Chick-embryo Fibroblasts. Novel Mechanism for the Stimulation of Glycolysis by Retroviruses. Biochem. J. 1986, 236, 595-599.
158. Kole, H. K.; Resnick, R. J.; Van Doren, M.; Racker, E. Regulation of 6-phosphofructo-1-kinase Activity in Ras-transformed Rat-1 Fibroblasts. Arch. Biochem. Biophys. 1991, 286, 586-590.
159. Norris, J. L.; Baldwin, A. S., Jr. Oncogenic Ras Enhances NF-kappa B Transcriptional Activity through Raf-dependent and Raf-independent Mitogen-activated Protein Kinase Signaling Pathways. J. Biol. Chem. 1999, 274, 13841-13846.
160. Sears, R.; Leone, G.; DeGregori, J.; Nevins, J. R. Ras Enhances Myc Protein Stability. Mol. Cell. 1999, 3, 169-179.
161. Sears, R.; Nuckolls, F.; Haura, E.; Taya, Y.; Tamai, K.; Nevins, J. R. Multiple Ras-dependent Phosphorylation Pathways Regulate Myc Protein Stability. Genes Dev. 2000, 14, 2501-2514.
162. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, Oxygen and Nutrient Supply and Metabolic Microenvironment of Human Tumors: A Review. Cancer Res. 1989, 49, 6449-6465.
163. Izuishi, K.; Kato, K.; Ogura, T.; Kinoshita T.; Esumi, H. Remarkable Tolerance of Tumor Cells to Nutrient Deprivation: Possible New Biochemical Target for Cancer Therapy. Cancer Res. 2000, 60, 6201-6207.
164. Gottlob, K.; Majewski, N.; Kennedy, S.; Kandel, E.; Robey, R. B.; Hay, N. Inhibition of Early Apoptotic Events by Akt/PKB is Dependent on the First Committed Step of Glycolysis and Mitochondrial Hexokinase. Genes Dev. 2001, 15, 1406-1418.
165. Minchenko, A.; Leshchinsky, I.; Opentanova, I.; Sang, N.; Srinivas, V.; Armstead, V.; Caro, J. Hypoxia-inducible Factor-1-mediated Expression of the 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) Gene. Its Possible Role in the Warburg Effect. J. Biol. Chem. 2002, 277, 6183-6187.
166. Atsumi, T.; Chesney, J.; Metz, C.; Leng, L.; Donnelly, S.; Makita, Z.; Mitchell, R.; Bucala, R. High Expression of Inducible 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (iPFK-2; PFKFB3) in Human Cancers. Cancer Res. 2002, 62, 5881-5887.
167. Wang, W.; Caldwell, M. C.; Lin, S.; Furneaux, H.; Gorospe, M. HuR Regulates Cyclin A and Cyclin B1 mRNA Stability During Cell Proliferation. EMBO J. 2000, 19, 2340-2350.
168. Papapetropoulos, A.; Fulton, D.; Mahboubi, K.; Kalb, R. G.; O'Connor, D. S.; Li, F.; Altieri, D. C.; Sessa, W. C. Angiopoietin-1 Inhibits Endothelial Cell Apoptosis Via the Akt/survivin Pathway. J. Biol. Chem. 2000, 275, 9102-9105.
169. Kim, I.; Kim, H. G.; So, J. N.; Kim, J. H.; Kwak, H. J.; Koh, G. Y. Angiopoietin-1 Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway. Circ. Res. 2000, 86, 24-29.
170. Fujio, Y.; Walsh, K. Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner. J. Biol. Chem. 1999, 274, 16349-16354.
171. Fulton, D.; Gratton, J. P.; McCabe, T. J.; Fontana, J.; Fujio, Y.; Walsh, K.; Franke, T. F.; Papapetropoulos, A.; Sessa, W. C. Regulation of Endothelium-derived Nitric Oxide Production by the Protein Kinase Akt. Nature 1999, 399, 597-601.
172. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A. M. Activation of Nitric Oxide Synthase in Endothelial Cells by Akt-dependent Phosphorylation. Nature 1999, 399, 601-605.
173. Michell, B. J.; Griffiths, J. E.; Mitchelhill, K. I.; Rodriguez-Crespo, I.; Tiganis, T.; Bozinovski, S.; de Montellano, P. R.; Kemp, B. E.; Pearson, R. B. The Akt Kinase Signals Directly to Endothelial Nitric Oxide Synthase. Curr. Biol. 1999, 9, 845-848.
174. Dimmeler, S.; Zeiher, A. M. Akt Takes Center Stage in Angiogenesis Signaling. Circ. Res. 2000, 86, 4-5.
175. Wen, S.; Stolarov, J.; Myers, M. P.; Su, J. D.; Wigler, M. H.; Tonks, N. K.; Durden, D. L. PTEN Controls Tumor-induced Angiogenesis. Proc. Natl. Acad. Sci. USA 2001, 98, 4622-4627.
176. Zelzer, E.; Levy, Y.; Kahana, C.; Shilo, B. Z.; Rubinstein, M.; Cohen, B. Insulin Induces Transcription of Target Genes through the Hypoxia-inducible Factor HIF-1alpha/ARNT. Embo J. 1998, 17, 5085-5094.
177. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M. M.; Simons, J. W.; Semenza, G. L. Modulation of Hypoxia-inducible Factor 1alpha Expression by the Epidermal Growth Factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP Pathway in Human Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics. Cancer Res. 2000, 60, 1541-1545.
178. Zundel, W.; Schindler, C.; Haas-Kogan, D.; Koong, A.; Kaper, F.; Chen, E.; Gottschalk, A. R.; Ryan, H. E.; Johnson, R. S.; Jefferson, A. B.; Stokoe, D.; Giaccia, A. J. Loss of PTEN Facilitates HIF-1-mediated Gene Expression. Genes Dev. 2000, 14, 391-396.
179. Laughner, E.; Taghavi, P.; Chiles, K.; Mahon, P. C.; Semenza, G. L. HER2 (neu) Signaling Increases the Rate of Hypoxia-inducible Factor 1alpha (HIF-1alpha) Synthesis: Novel Mechanism for HIF-1-mediated Vascular Endothelial Growth Factor Expression. Mol. Cell Biol. 2001, 21, 3995-4004.
180. Bellacosa, A.; de Feo, D.; Godwin, A. K.; Bell, D. W.; Cheng, J. Q.; Altomare, D. A.; Wan, M.; Dubeau, L.; Scambia, G.; Masciullo, V.; et al. Molecular Alterations of the AKT2 Oncogene in Ovarian and Breast Carcinomas. Int. J. Cancer 1995, 64, 280-285.
181. Cheng, J. Q.; Ruggeri, B.; Klein, W. M.; Sonoda, G.; Altomare, D. A.; Watson, D. K.; Testa, J. R. Amplification of AKT2 in Human Pancreatic Cells and Inhibition of AKT2 Expression and Tumorigenicity by Antisense RNA. Proc. Natl. Acad. Sci. USA 1996, 93, 3636-3641.
182. Ruggeri, B. A.; Huang, L.; Wood, M.; Cheng, J. Q.; Testa, J. R. Amplification and Overexpression of the AKT2 Oncogene in a Subset of Human Pancreatic Ductal Adenocarcinomas. Mol. Carcinog. 1998, 21, 81-86.
183. Nakatani, K.; Thompson, D. A.; Barthel, A.; Sakaue, H.; Liu, W.; Weigel, R. J.; Roth, R. A. Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines. J. Biol. Chem. 1999, 274, 21528-21532.
184. Kauffmann-Zeh, A.; Rodriguez-Viciana, P.; Ulrich, E.; Gilbert, C.; Coffer, P.; Downward, J.; Evan, G. Suppression of c-Myc-induced Apoptosis by Ras Signalling through PI(3)K and PKB. Nature 1997, 385, 544-548.
185. Shayesteh, L.; Lu, Y.; Kuo, W. L.; Baldocchi, R.; Godfrey, T.; Collins, C.; Pinkel, D.; Powell, B.; Mills, G. B.; Gray, J. W. PIK3CA is Implicated as an Oncogene in Ovarian Cancer. Nat. Genet. 1999, 21, 99-102.
186. Ma, Y. Y.; Wei, S. J.; Lin, Y. C.; Lung, J. C.; Chang, T. C.; Whang-Peng, J.; Liu, J. M.; Yang, D. M.; Yang, W. K.; Shen, C. Y. PIK3CA as an Oncogene in Cervical Cancer. Oncogene 2000, 19, 2739-2744.
187. Blume-Jensen, P.; Hunter, T. Oncogenic Kinase Signalling. Nature 2001, 411, 355-365.
188. Harari, D.; Yarden, Y. Molecular Mechanisms Underlying ErbB2/HER2 Action in Breast Cancer. Oncogene 2000, 19, 6102-6114.
189. Siegel, P. M.; Ryan, E. D.; Cardiff, R. D.; Muller, W. J. Elevated Expression of Activated Forms of Neu/ErbB-2 and ErbB-3 are Involved in the Induction of Mammary Tumors in Transgenic Mice: Implications for Human Breast Cancer. EMBO J. 1999, 18, 2149-2164.
190. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB Signaling Network: Receptor Heterodimerization in Development and Cancer. EMBO J. 2000, 19, 3159-3167.
191. Prigent, S. A.; Gullick, W. J. Identification of c-erbB-3 Binding Sites for Phosphatidylinositol 3′-kinase and SHC Using an EGF Receptor/c-erbB-3 Chimera. EMBO J. 1994, 13, 2831-2841.
192. Zhou, B. P.; Hu, M. C.; Miller, S. A.; Yu, Z.; Xia, W.; Lin, S. Y.; Hung, M. C. HER-2/ncu Blocks Tumor Necrosis Factor-induced Apoptosis Via the Akt/NF-kappaB Pathway. J. Biol. Chem. 2000, 275, 8027-8031.
193. Hu, Y.; Qiao, L.; Wang, S.; Rong, S. B.; Meuillet, E. J.; Berggren, M.; Gallegos, A.; Powis, G.; Kozikowski, A. P. 3-(Hydroxymethyl)-bearing Phosphatidylinositol Ether Lipid Analogues and Carbonate Surrogates Block PI3-K, Akt, and Cancer Cell Growth. J. Med. Chem. 2000, 43, 3045-3051.
194. Hu, Y.; Meuillet, E. J.; Berggren, M.; Powis, G.; Kozikowski, A. P. 3-Deoxy-3-substituted-D-myo-inositol Imidazolyl Ether Lipid Phosphates and Carbonate as Inhibitors of the Phosphatidylinositol 3-kinase Pathway and Cancer Cell Growth. Bioorg. Med. Chem. Lett. 2001, 11, 173-176.
195. Rong, S. B.; Hu, Y.; Enyedy, I.; Powis, G.; Meuillet, E. J.; Wu, X.; Wang, R.; Wang, S.; Kozikowski, A. P. Molecular Modeling Studies of the Akt PH Domain and its Interaction with Phosphoinositides. J. Med. Chem. 2001, 44, 898-908.
196. Kozikowski, A. P.; Sun, H.; Brognard, J.; Dennis, P. A. Novel PI Analogues Selectively Block Activation of the Pro-survival Serine/Threonine Kinase Akt. J. Am. Chem. Soc. 2003, 125, 1144-1145.
197. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N. Engl. J. Med. 2001, 344, 1031-1037.
198. Demetri, G. D.; von Mehren, M.; Blanke, C. D.; Van den Abbeele, A. D.; Eisenberg, B.; Roberts, P. J.; Heinrich, M. C.; Tuveson, D. A.; Singer, S.; Janicek, M.; Fletcher, J. A.; Silverman, S. G.; Silberman, S. L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B. J.; Corless, C.; Fletcher, C. D.; Joensuu, H. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. N. Engl. J. Med. 2002, 347, 472-480.
199. Ottmann, O. G.; Druker, B. J.; Sawyers, C. L.; Goldman, J. M.; Reiffers, J.; Silver, R. T.; Tura, S.; Fischer, T.; Deininger, M. W.; Schiffer, C. A.; Baccarani, M.; Gratwohl, A.; Hochhaus, A.; Hoelzer, D.; Fernandes-Reese, S.; Gathmann, I.; Capdeville, R.; O'Brien, S. G. A Phase 2 Study of Imatinib in Patients With Relapsed or Refractory Philadelphia Chromosome-positive Acute Lymphoid Leukemias. Blood 2002, 100, 1965-1971.
200. Sawyers, C. L.; Hochhaus, A.; Feldman, E.; Goldman, J. M.; Miller, C. B. ; Ottmann, O. G.; Schiffer, C. A.; Talpaz, M.; Guilhot, F.; Deininger, M. W.; Fischer, T.; O'Brien, S. G.; Stone, R. M.; Gambacorti-Passerini, C. B.; Russell, N. H.; Reiffers, J. J.; Shea, T. C.; Chapuis, B.; Coutre, S.; Tura, S.; Morra, E.; Larson, R. A.; Saven, A.; Peschel, C.; Gratwohl, A.; Mandelli, F.; Ben-Am, M.; Gathmann, I.; Capdeville, R.; Paquette, R. L.; Druker, B. J. Imatinib Induces Hematologic and Cytogenetic Responses in Patients With Chronic Myelogenous Leukemia in Myeloid Blast Crisis: Results of a Phase II Study. Blood 2002, 99, 3530-3539.
201. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal Structure of an Activated Akt/protein Kinase B Ternary Complex With GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 2002, 9, 940-944.
202. Huang, X.; Begley, M.; Morgenstern, K. A.; Gu, Y.; Rose, P.; Zhao, H.; Zhu, X. Crystal Structure of an Inactive Akt2 Kinase Domain. Structure (Camb.) 2003, 11, 21-30.
203. Chen, W. S.; Xu, P. Z.; Gottlob, K.; Chen, M. L.; Sokol, K.; Shiyanova, T.; Roninson, I.; Weng, W.; Suzuki, R.; Tobe, K.; Kadowaki, T.; Hay, N. Growth Retardation and Increased Apoptosis in Mice With Homozygous Disruption of the Akt1 Gene. Genes Dev. 2001, 15, 2203-2208.
204. Cho, H.; Mu, J.; Kim, J. K.; Thorvaldsen, J. L.; Chu, Q.; Crenshaw, E. B., 3rd; Kaestner, K. H.; Bartolomei, M. S.; Shulman, G. I.; Birnbaum, M. J. Insulin Resistance and a Diabetes Mellitus-like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKB beta). Science 2001, 292, 1728-1731.
205. Cho, H.; Thorvaldsen, J. L.; Chu, Q.; Feng, F.; Birnbaum, M. J. Akt1/PKBalpha is Required for Normal Growth But Dispensable for Maintenance of Glucose Homeostasis in Mice. J. Biol. Chem. 2001, 276, 38349-38352.
206. Reith, A. D.; Rottapel, R.; Giddens, E.; Brady, C.; Forrester, L.; Bernstein, A. W Mutant Mice With Mild or Severe Developmental Defects Contain Distinct Point Mutations in the Kinase Domain of the C-kit Receptor. Genes Dev. 1990, 4, 390-400.
207. Reith, A. D.; Ellis, C.; Lyman, S. D.; Anderson, D. M.; Williams, D. E.; Bernstein, A.; Pawson, T. Signal Transduction By Normal Isoforms and W Mutant Variants of the Kit Receptor Tyrosine Kinase. EMBO J. 1991, 10, 2451-2459.
208. Motro, B.; van der Kooy, D.; Rossant, J.; Reith, A.; Bernstein, A. Contiguous Patterns of C-kit and Steel Expression: Analysis of Mutations at the W and SI Loci. Development 1991, 113, 1207-1221.
209. Tybulewicz, V. L.; Crawford, C. E.; Jackson, P. K.; Bronson, R. T.; Mulligan, R. C. Neonatal Lethality and Lymphopenia in Mice With a Homozygous Disruption of the C-abl Proto-oncogene. Cell 1991, 65, 1153-1163.
210. Soriano, P. The PDGF Alpha Receptor is rRquired For Neural Crest Cell Development and For Normal Patterning of the Somites. Development 1997, 124, 2691-2700.
211. Drevs, J.; Hofmann, I.; Hugenschmidt, H.; Wittig, C.; Madjar, H.; Muller, M.; Wood, J.; Martiny-Baron, G.; Unger, C.; Marme, D. Effects of PTK787/ZK 222584, A Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, On Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model. Cancer Res. 2000, 60, 4819-4824.
212. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J. ; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, A Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth After Oral Administration. Cancer Res 2000, 60, 2178-2189.
213. Ozaki, H.; Seo, M. S.; Ozaki, K.; Yamada, H.; Yamada, E.; Okamoto, N.; Hofmann, F.; Wood, J. M.; Campochiaro, P. A. Blockade of Vascular Endothelial Cell Growth Factor Receptor Signaling is Sufficient to Completely Prevent Retinal Neovascularization. Am. J. Pathol. 2000, 156, 697-707.
214. Hess, C.; Vuong, V.; Hegyi, I.; Riesterer, O.; Wood, J.; Fabbro, D.; Glanzmann, C.; Bodis, S.; Pruschy, M. Effect of VEGF Receptor Inhibitor PTK787/ZK222584 [correction of ZK222548] Combined With Ionizing Radiation on Endothelial Cells and Tumour Growth. Br. J. Cancer 2001, 85, 2010-2016.
215. Liliental, J.; Moon, S. Y.; Lesche, R.; Mamillapalli, R.; Li, D.; Zheng, Y.; Sun, H.; Wu, H. Genetic Deletion of the Pten Tumor Suppressor Gene Promotes Cell Motility by Activation of Rac1 and Cdc42 GTPases. Curr. Biol. 2000, 10, 401-404.
216. Welch, H.; Eguinoa, A.; Stephens, L. R.; Hawkis, P. T. Protein Kinase Band Rac Are Activated In Parallel Within A Phosphatidylinositide 3OH-kinase-controlled Signaling Pathway. J. Biol. Chem. 1998, 273, 11248-11256.
217. Brunet, A.; Park, J.; Tran, H.; Hu, L. S.; Flemmings, B. A.; Greenberg, M. E. Protein Kinase SGK Mediates Survival Signals By Phosphorylating the Forkhead Transcription Factor FKHRL1 (FOXO3a). Mol. Cell Biol. 2001, 21, 952-965.
218. Park, J.; Leong, M. L.; Buse, P.; Maiyar, A. C.; Firestone, G. L.; Hemmings, B. A. Serum and Glucocorticoid-inducible Kinase (SGK) is a Target of the PI 3-kinase-Stimulated Signaling Pathway. EMBO J. 1999, 18, 3024-3033.
219. Fujita, N.; Sato, S.; Ishida, A.; Tsuruo, T. Involvement of Hsp90 in Signaling and Stability of 3-phosphoinositide-dependent Kinase-1. J. Biol. Chem. 2002, 277, 10346-10353.
220. Sato, S.; Fujita, N.; Tsuruo, T. Regulation of Kinase Activity of 3-phosphoinositide-dependent Protein Kinase-1 by Binding to 14-3-3. J. Biol. Chem. 2002, 277, 39360-39367.
221. Basso, A. D.; Solit, D. B.; Chiosis, G.; Giri, B.; Tsichlis, P.; Rosen, N. Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and is Destabilized by Inhibitors of Hsp90 Function. J. Biol. Chem. 2002, 277, 39858-39866.
222. Basso, A. D.; Solit, D. B.; Munster, P. N.; Rosen, N. Ansamycin Antibiotics Inhibit Akt Activation and Cyclin D Expression in Breast Cancer Cells That Overexpress HER2. Oncogene 2002, 21, 1159-1166.
223. Mitsiades, C. S.; Mitsiades, N.; Poulaki, V.; Akiyiama, M.; Treon, S. P. ; Anderson, K. C. The Hsp90 Molecular Chaperone as a Novel Therapeutic Target in Hematologic Malignancies. Blood 2001, 11S, 377a.
224. Mitsiades, C. S.; Mitsiades, N.; Poulaki, V.; Fanourakis, G.; Hideshima, T.; Chauhan, D.; Munshi, N. C.; Anderson, K. C. Hsp90 Inhibitors Prolong Survival in a SCID/NOD Micc Model of Diffuse Multiple Myeloma: Therapeutic Implications. Blood 2002, 100, 106a.
225. Kuduk, S. D.; Harris, T. C.; Zheng, F. F.; Sepp-Lorenzino, L.; Ouerfelli, Q.; Rosen, N.; Danishefsky, S. J. Synthesis and Evaluation of Geldanamycin-testosterone Hybrids. Bioorg. Med. Chem. Lett. 2000, 10, 1303-1306.
226. Veldscholte, J.; Berrevoets, C. A.; Mulder, E. Studies on the Human Prostatic Cancer Cell Line LNCaP. J. Steroid. Biochem. Mol. Biol. 1994, 49, 341-346.
227. Marivoet, S.; Van Dijck, P.; Verhoeven, G.; Heyns, W. Interaction of the 90-kDa Heat Shock Protein with Native and In Vitro Translated Androgen Receptor and Receptor Fragments. Mol. Cell. Endocrinol. 1992, 88, 165-174.
228. Solit, D. B.; Zheng, F. F.; Drobnjak, M.; Munster, P. N.; Higgins, B.; Verbel, D.; Heller, G.; Tong, W.; Cordon-Cardo, C.; Agus, D. B.; Scher, H. I.; Rosen, N. 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts. Clin. Cancer Res. 2002, 8, 986-993.
229. Vanaja, D. K.; Mitchell, S. H.; Toft, D. O.; Young, C. Y. Effect of Geldanamycin on Androgen Receptor Function and Stability. Cell Stress Chaperones 2002, 7, 55-64.
230. Lee, M. O.; Kim, E. O.; Kwon, H. J.; Kim, Y. M.; Kang, H. J.; Kang, H.; Lee, J. E. Radicicol Represses the Transcriptional Function of the Estrogen Receptor by Suppressing the Stabilization of the Receptor by Heat Shock Protein 90. Mol. Cell Endocrinol. 2002, 188, 47-54.
231. Zheng, F. F.; Kuduk, S. D.; Chiosis, G.; Munster, P. N.; Sepp-Lorenzino, L.; Danishefsky, S. J.; Rosen, N. Identification of a Geldanamycin Dimer that Induces the Selective Degradation of HER-family Tyrosine Kinases. Cancer Res. 2000, 60, 2090-2094.
232. Bagatell, R.; Khan, O.; Paine-Murrieta, G.; Taylor, C. W.; Akinaga, S.; Whitesell, L. Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs: A Ligand-independent Approach to Hormonal Therapy of Breast Cancer. Clin. Cancer Res. 2001, 7, 2076-2084.
233. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N. A Small Molecule Designed to Bind to the Adenine Nucleotide Pocket of Hsp90 Causes Her2 Degradation and the Growth Arrest and Differentiation of Breast Cancer Cells. Chem. Biol. 2001, 8, 289-299.
234. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a Purine-scaffold Novel Class of Hsp90 Binders that Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine Kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
235. Citri, A.; Alroy, I.; Lavi, S.; Rubin, C.; Xu, W.; Grammatikakis, N.; Patterson, C.; Neckers, L.; Fry, D. W.; Yarden, Y. Drug-induced Ubiquitylation and Degradation of ErbB Receptor Tyrosine Kinases: Implications for Cancer Therapy. EMBO J. 2002, 21, 2407-2417.
236. Nguyen, D. M.; Lorang, D.; Chen, G. A.; Stewart, J. H. T.; Tabibi, E.; Schrump, D. S. Enhancement of Paclitaxel-mediated Cytotoxicity in Lung Cancer Cells by 17-allylamino Geldanamycin: In Vitro and In Vivo Analysis. Ann. Thorac. Surg. 2001, 72, 371-378; discussion 378-379.
237. Podsypanina, K.; Lee, R. T.; Politis, C.; Hennessy, I.; Crane, A.; Puc, J.; Neshat, M.; Wang, H.; Yang, L.; Gibbons, J.; Frost, P.; Dreisbach, V.; Blenis, J.; Gaciong, Z.; Fisher, P.; Sawyers, C.; Hedrick-Ellenson, L.; Parsons, R. An Inhibitor of mTOR Reduces Neoplasia and Normalizes p70/S6 Kinase Activity in Pten+/-mice. Proc. Natl. Acad. Sci. USA 2001, 98, 10320-10325.
238. Yu, K.; Toral-Barza, L.; Discafani, C.; Zhang, W. G.; Skotnicki, J.; Frost, P.; Gibbons, J. J. mTOR, A Novel Target in Breast Cancer: The Effect of CCI-779, An mTOR Inhibitor, in Preclinical Models of Breast Cancer. Endocr. Relat. Cancer 2001, 8, 249-258.
239. Elit, L. CCI-779 Wyeth. Curr. Opin. Investig. Drugs 2002, 3, 1249-1253.
240. Sun, M.; Wang, G.; Paciga, J. E.; Feldman, R. I.; Yuan, Z. Q.; Ma, X. L. ; Shelley, S. A.; Jove, R.; Tsichlis, P. N.; Nicosia, S. V.; Cheng, J. Q. AKT1/PKBalpha Kinase is Frequently Elevated in Human Cancers and its Constitutive Activation is Required for Oncogenic Transformation in NIH3T3 Cells. Am. J. Pathol. 2001, 159, 431-437.
241. Barlund, M.; Monni, O.; Kononen, J.; Cornelison, R.; Torhorst, J.; Sauter, G.; Kallioniemi, O.-P.; Kallioniemi, A. Multiple Genes at 17q23 Undergo Amplification and Overexpression in Breast Cancer. Cancer Res. 2000, 60, 5340-5344.
242. Barlund, M.; Forozan, F.; Kononen, J.; Bubendorf, L.; Chen, Y.; Bittner, M. L.; Torhorst, J.; Haas, P.; Bucher, C.; Sauter, G.; Kallioniemi, O. P.; Kallioniemi, A. Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray Analysis. J. Natl. Cancer Inst. 2000, 92, 1252-1259.
243. Monni, O.; Barlund, M.; Mousses, S.; Kononen, J.; Sauter, G.; Heiskanen, M.; Paavola, P.; Avela, K.; Chen, Y.; Bittner, M. L.; Kallioniemi, A. Comprehensive Copy Number and Gene Expression Profiling of the 17q23 Amplicon in Human Breast Cancer. Proc. Natl. Acad. Sci. USA 2001, 98, 5711-5716.
244. Teng, D. H.; Hu, R.; Lin, H.; Davis, T.; Iliev, D.; Frye, C.; Swedlund, B.; Hansen, K. L.; Vinson, V. L.; Gumpper, K. L.; Ellis, L.; El-Naggar, A.; Frazier, M.; Jasser, S.; Langford, L. A.; Lee, J.; Mills, G. B.; Pershouse, M. A.; Pollack, R. E.; Tornos, C.; Troncoso, P.; Yung, W. K.; Fujii, G.; Berson, A.; Bookstein, R.; Bolen, J. B.; Tavtgian, S. V.; Steck, P. A. MMACI/PTEN Mutations in Primary Tumor Specimens and Tumor Cell Lines. Cancer Res. 1997, 57, 5221-5225.
245. Hahn, M.; Wieland, I.; Koufaki, O. N.; Gorgens, H.; Sobottka, S. B.; Schackert, G.; Schackert, H. K. Genetic Alterations of the Tumor Suppressor Gene PTEN/MMACI in Human Brain Metastases. Clin. Cancer Res. 1999, 5, 2431-2437.
246. Sun, M.; Paciga, J. E.; Feldman, R. I.; Yuan, Z.; Coppola, D.; Lu, Y. Y. ; Shelley, S. A.; Nicosia, S. V.; Cheng, J. Q. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, Activated in Breast Cancer, Regulates and is Induced by Estrogen Receptor Alpha (ERalpha) Via Interaction between ERalpha and PI3K. Cancer Res. 2001, 61, 5985-5991.
247. Rubin, M. A.; Gerstein, A.; Reid, K.; Bostwick, D. G.; Cheng, L.; Parsons, R.; Papadopoulos, N. 10q23.3 Loss of Heterozygosity is Higher in Lymph Node-positive (pT2-3,N+) Versus Lymph Node-negative (pT2-3,N0) Prostate Cancer. Hum. Pathol. 2000, 31, 504-508.
248. Kohno, T.; Takahashi, M.; Manda, R.; Yokota, J. Inactivation of the PTEN/MMACI/TEPI Gene in Human Lung Cancers. Genes Chromosomes Cancer 1998, 22, 152-156.
249. Soria, J. C.; Lee, H. Y.; Lee, J. I.; Wang, L.; Issa, J. P.; Kemp, B. L. ; Liu, D. D.; Kurie, J. M.; Mao, L.; Khuri, F. R. Lack of PTEN Expression in Non-small Cell Lung Cancer could be Related to Promoter Methylation. Clin. Cancer Res. 2002, 8, 1178-1184.
250. Okami, K.; Wu, L.; Riggins, G.; Cairns, P.; Goggins, M.; Evron, E.; Halachmi, N.; Ahrendt, S. A.; Reed, A. L.; Hilgers, W.; Kern, S. E.; Koch, W. M.; Sidransky, D.; Jen, J. Analysis of PTEN/MMACI Alterations in Aerodigestive Tract Tumors. Cancer Res. 1998, 58, 509-511.
251. Petersen, S.; Rudolf, J.; Bockmuhl, U.; Gellert, K.; Wolt, G.; Dietel, M.; Petersen, I. Distinct Regions of Allelic Imbalance on Chromosome 10q22-q26 in Squamous Cell Carcinomas of the Lung. Oncogene 1998, 17, 449-454.
252. Saito, M.; Okamoto, A.; Kohno, T.; Takakura, S.; Shinozaki, H.; Isonishi, S.; Yasuhara, T.; Yoshimura, T.; Ohtake, Y.; Ochiai, K.; Yokota, J.; Tanaka, T. Allelic Imbalance and Mutations of the PTEN Gene in Ovarian Cancer. Int. J. Cancer 2000, 85, 160-165.
253. Philp, A. J.; Campbell, I. G.; Leet, C.; Vincan, E.; Rockman, S. P.; Whitehead, R. H.; Thomas, R. J.; Phillips, W. A. The Phosphatidylinositol 3′-kinase p85alpha Gene is an Oncogene in Human Ovarian and Colon Tumors. Cancer Res. 2001, 61, 7426-7429.
254. Yokoyama, Y.; Wan, X.; Shinohara, A.; Takahashi, S.; Takahashi, Y.; Niwa, K.; Tamaya, T. Expression of PTEN and PTEN Pseudogene in Endometrial Carcinoma. Int. J. Mol. Med. 2000, 6, 47-50.
255. Salvesen, H. B.; Stefansson, I.; Kalvenes, M. B.; Das, S.; Akslen, L. A. Loss of PTEN Expression is Associated with Metastatic Disease in Patients with Endometrial Carcinoma. Cancer 2002, 94, 2185-2191.
256. Salvesen, H. B.; MacDonald, N.; Ryan, A.; Jacobs, I. J.; Lynch, E. D.; Akslen, L. A.; Das, S. PTEN Methylation is Associated with Advanced Stage and Microsatellite Instability in Endometrial Carcinoma. Int. J. Cancer 2001, 91, 22-26.
257. Celebi, J. T.; Shendrik, I.; Silvers, D. N.; Peacocke, M. Identification of PTEN Mutations in Metastatic Melanoma Specimens. J. Med. Genet. 2000, 37, 653-657.
258. Guldberg, P.; thor Straten, P.; Birck, A.; Ahrenkiel, V.; Kirkin, A. F.; Zeuthen, J. Disruption of the MMACI/PTEN Gene by Deletion or Mutation is a Frequent Event in Malignant Melanoma. Cancer Res. 1997, 57, 3660-3663.
259. Tsao, H.; Zhang, X.; Benoit, E.; Haluska, F. G. Identification of PTEN/MMACI Alterations in Uncultured Melanomas and Melanoma Cell Lines. Oncogene 1998, 16, 3397-3402.
260. Birck, A.; Ahrenkiel, V.; Zeuthen, J.; Hou-Jensen, K.; Guldberg, P. Mutation and Allelic Loss of the PTEN/MMACI Gene in Primary and Metastatic Melanoma Biopsies. J. Invest. Dermatol. 2000, 114, 277-280.
261. Tsao, H.; Zhang, X.; Fowlkes, K.; Haluska, F. G. Relative Reciprocity of NRAS and PTEN/MMACI Alterations in Cutaneous Melanoma Cell Lines. Cancer Res. 2000, 60, 1800-1804.
262. Zhou, X. P.; Gimm, O.; Hampel, H.; Niemann, T.; Walker, M. J.; Eng, C. Epigenetic PTEN Silencing in Malignant Melanomas Without PTEN Mutation. Am. J. Pathol. 2000, 157, 1123-1128.
263. Robertson, G. P.; Furnari, F. B.; Miele, M. E.; Glendening, M. J.; Welch, D. R.; Fountain, J. W.; Lugo, T. G.; Huang, H. J.; Cavenee, W. K. In Vitro Loss of Heterozygosity Targets the PTEN/MMACI Gene in Melanoma. Proc. Natl. Acad. Sci. USA 1998, 95, 9418-9423.
264. Reifenberger, J.; Wolter, M.; Bostrom, J.; Buschges, R.; Schulte, K. W.; Megahed, M.; Ruzicka, T.; Reifenberger, G. Allelic Losses on Chromosome Arm 10q and Mutation of the PTEN (MMACI) Tumour Suppressor Gene in Primary and Metastatic Malignant Melanomas. Virchows Arch. 2000, 436, 487-493.
265. Jiang, Y. A.; Fan, L. F.; Jiang, C. Q.; Zhang, Y. Y.; Luo, H. S.; Tang, Z. J.; Xia, D.; Wang, M. Expression and Significance of PTEN, Hypoxia-inducible Factor-1 Alpha in Colorectal Adenoma and Adenocarcinoma. World J. Gastroenterol. 2003, 9, 491-494.
266. Chang, J. G.; Chen, Y. J.; Perng, L. I.; Wang, N. M.; Kao, M. C.; Yang, T. Y.; Chang, C. P.; Tsai, C. H. Mutation Analysis of the PTEN/MMACI Gene in Cancers of the Digestive Tract. Eur. J. Cancer 1999, 35, 647-651.
267. Yao, Y. J.; Ping, X. L.; Zhang, H.; Chen, F. F.; Lee, P. K.; Ahsan, H.; Chen, C. J.; Lee. P. H.; Peacocke, M.; Santella, R. M.; Tsou, H. C. PTEN/MMACI Mutations in Hepatocellular Carcinomas. Oncogene 1999, 18, 3181-3185.
268. Kawamura, N.; Nagai, H.; Bando, K.; Koyama, M.; Matsumoto, S.; Tajiri, T.; Onda, M.; Fujimoto, J.; Ueki, T.; Konishi, N.; Shiba, T.; Emi, M. PTEN/ MMACI Mutations in Hepatocellular Carcinomas: Somatic Inactivation of Both Alleles in Tumors. Jpn. J. Cancer Res. 1999, 90, 413-418.
269. Fujiwara, Y.; Hoon, D. S.; Yamada, T.; Umeshita, K.; Gotoh, M.; Sakon, M.; Nishisho, I.; Monden, M. PTEN/MMACI Mutation and Frequent Loss of Heterozygosity Identified in Chromosome 10q in a Subset of Hepatocellular Carcinomas. Jpn. J. Cancer Res. 2000, 91, 287-292.
270. Schagdarsurengin, U.; Wilkens, L.; Steinemann, D.; Flemming, P.; Kreipe, H. H.; Pfeifer, G. P.; Schlegelberger, B.; Dammann, R. Frequent Epigenetic Inactivation of the RASSFIA Gene in Hepatocellular Carcinoma. Oncogene 2003, 22, 1866-1871.
271. Liaw, D.; Marsh, D. J.; Li, J.; Dahia, P. L.; Wang, S. I.; Zheng, Z.; Bose, S.; Call, K. M.; Tsou, H. C.; Peacocke, M.; Eng, C.; Parsons, R. Germline Mutations of the PTEN Gene in Cowden Disease, an Inherited Breast and Thyroid Cancer Syndrome. Nat. Genet. 1997, 16, 64-67.
272. Nelen, M. R.; van Staveren, W. C.; Peeters, E. A.; Hassel, M. B.; Gorlin, R. J.; Hamm, H.; Lindboe, C. F.; Fryns, J. P.; Sijmons, R. H.; Woods, D. G.; Mariman, E. C.; Padberg, G. W.; Kremer, H. Germline Mutations in the PTEN/MMACI Gene in Patients with Cowden Disease. Hum. Mol. Genet. 1997, 6, 1383-1387.
273. Marsh, D. J.; Coulon, V.; Lunetta, K. L.; Rocca-Serra, P.; Dahia, P. L.; Zheng, Z.; Liaw, D.; Caron, S.; Duboue, B.; Lin, A. Y.; Richardson, A. L.; Bonnetblanc, J. M.; Bressieux, J. M.; Cabarrot-Moreau, A.; Chompret, A.; Demange, L.; Eeles, R. A.; Yahanda, A. M.; Fearon, E. R.; Fricker, J. P.; Gorlin, R. J.; Hodgson, S. V.; Huson, S.; Lacombe, D.; Eng, C. Mutation Spectrum and Genotype-phenotype Analyses in Cowden Disease and Bannayan-Zonana Syndrome, Two Hamartoma Syndromes with Germline PTEN Mutation. Hum. Mol. Genet. 1998, 7, 507-515.
274. Dahia, P. L.; Marsh, D. J.; Zheng, Z.; Zedenius, J.; Komminoth, P.; Frisk, T.; Wallin, G.; Parsons, R.; Longy, M.; Larsson, C.; Eng, C. Somatic Deletions and Mutations in the Cowden Disease Gene, PTEN, in Sporadic Thyroid Tumors. Cancer Res. 1997, 57, 4710-4713.
275. Halachmi, N.; Halachmi, S.; Evron, E.; Cairns, P.; Okami, K.; Saji, M.; Westra, W. H.; Zeiger, M. A.; Jen, J.; Sidransky, D. Somatic Mutations of the PTEN Tumor Suppressor Gene in Sporadic Follicular Thyroid Tumors. Genes Chromosomes Cancer 1998, 23, 239-243.
276. Hsieh, M. C.; Lin, S. F.; Shin, S. J.; Liu, T. C.; Chang, J. G.; Lee, J. P. Mutation Analysis of PTEN/MMACI in Sporadic Thyroid Tumors. Koohsiung J. Med. Sci. 2000, 16, 9-12.
277. Frisk, T.; Foukakis, T.; Dwight, T.; Lundberg, J.; Hoog, A.; Wallin, G.; Eng, C.; Zedenius, J.; Larsson, C. Silencing of the PTEN Tumor-suppressor Gene in Anaplastic Thyroid Cancer. Genes Chromosomes Cancer 2002, 35, 74-80.
278. Eng, C. Role of PTEN, A Lipid Phosphatase Upstream Effector of Protein Kinase B, in Epithelial Thyroid Carcinogenesis. Ann. N. Y. Acad. Sci. 2002, 968, 213-221.
279. Bruni, P.; Boccia, A.; Baldassarre, G.; Trapasso, F.; Santoro, M.; Chiappetta, G.; Fusco, A.; Viglietto, G. PTEN Expression is Reduced in a Subset of Sporadic Thyroid Carcinomas: Evidence that PTEN-growth Suppressing Activity in Thyroid Cancer Cells Mediated by p27kip1. Oncogene 2000, 19, 3146-3155.
280. Ringel, M. D.; Hayre, N.; Saito, J.; Saunier, B.; Schuppert, F.; Burch, H.; Bernet, V.; Burman, K. D.; Kohn, L. D.; Saji, M. Overexpression and Overactivation of Akt in Thyroid Carcinoma. Cancer Res. 2001, 61, 6105-6111.
281. Wang, S. I.; Puc, J.; Li, J.; Bruce, J.N.; Cairns, P.; Sidransky, D.; Parsons, R. Somatic Mutations of PTEN in Glioblastoma Multiforme. Cancer Res. 1997, 57, 4183-4186.
282. Wang, L.; Ignat, A.; Axiotis, C. A. Differential Expression of the PTEN Tumor Suppressor Protein in Fetal and Adult Neuroendocrine Tissues and Tumors: Progressive Loss of PTEN Expression in Poorly Differentiated Neuroendocrine Neoplasms. Appl. Immunohistochem. Mol. Morphol. 2002, 10, 139-146.
283. Gronback, K.; Zeuthen, J.; Guldberg, P.; Ralfkiaer, E.; Hou-Jensen, K. Alterations of the MMACI/PTEN Gene in Lymphoid Malignancies. Blood 1998, 91, 4388-4390.
284. Nakahara, Y.; Nagai, H.; Kinoshita, T.; Uchida, T.; Hatano, S.; Murate, T.; Saito, H. Mutational Analysis of the PTEN/MMACI Gene in Non-Hodgkin's Lymphoma. Leukemia 1998, 12, 1277-1280.
285. Sakai, A.; Thieblemont, C.; Wellmann, A.; Jaffe, E. S.; Raffeld, M. PTEN Gene Alterations in Lymphoid Neoplasms. Blood 1998, 92, 3410-3415.
286. Butler, M. P.; Wang, S. I.; Chaganti, R. S.; Parsons, R.; Dalla-Favera, R. Analysis of PTEN Mutations and Deletions in B-cell Non-Hodgkin's Lymphomas.
287. Herranz, M.; Urioste, M.; Santos, J.; Martinez-Delgado, J. B.; Rivas, C. ; Benitez, J.; Fernandez-Piqueras, J. Allelic Losses and Genetic Instabilities of PTEN and p73 in Non-Hodgkin Lymphomas. Leukemia 2000, 14, 1325-1327.
288. Hyun, T.; Yam, A.; Pece, S.; Xie, X.; Zhang, J.; Miki, T.; Gutkind, J. S.; Li, W. Loss of PTEN Expression Leading to High Akt Activation in Human Multiple Myelomas. Blood 2000, 96, 3560-3568.
289. Jimenez, C.; Jones, D. R.; Rodriguez-Viciana, P.; Gonzalez-Garcia, A.; Leonardo, E.; Wennstrom, S.; von Kobbe, C.; Toran, J. L.; Calvo, V.; Copin, S. G.; Albar, J. P.; Gaspar, M. L.; Diez, E.; Marcos, M. A.; Downward, J.; Martinez, A. C.; Merida, I.; Carrera, A. C. Identitication and Characterization of a New Oncogene Derived from the Regulatory Subunit of Phosphoinositide 3-kinase. Embo J. 1998, 17, 743-753.
290. Boni, R.; Vortmeyer, A. O.; Burg, G.; Hofbauer, G.; Zhuang, Z. The PTEN Tumour Suppressor Gene and Malignant Melanoma. Melanoma Res. 1998, 8, 300-302.
291. Herbst, R. A.; Podewski, E. K.; Mommert, S.; Kapp, A.; Weiss, J. PTEN and MXII Allelic Loss on Chromosome 10q is Rare in Melanoma In Vivo. Arch. Dermatol. Res. 1999, 291, 567-569.
292. Poetsch, M.; Dittberner, T.; Woenckhaus, C. PTEN/MMACI in Malignant Melanoma and its Importance for Tumor Progression. Cancer Genet. Cytogenet. 2001, 125, 21-26.
293. Whiteman, D. C.; Zhou, X. P.; Cummings, M. C.; Pavey, S.; Hayward, N. K. ; Eng, C. Nuclear PTEN Expression and Clinicopathologic Features in a Population-based Series of Primary Cutaneous Melanoma. Int. J. Cancer 2002, 99, 63-67.
294. Deichmann, M.; Thome, M.; Benner, A.; Egner, U.; Hartschuh, W.; Naher, H. PTEN/MMACI Expression in Melanoma Resection Specimens. Br. J Cancer 2002, 87, 1431-1436.
295. Pollock, P. M.; Walker, G. J.; Glendening, J. M.; Que Noy, T.; Bloch, N. C.; Fountain, J. W.; Hayward, N. K. PTEN Inactivation is Rare in Melanoma Tumours but Occurs Frequently in Melanoma Cell Lines. Melanoma Res. 2002, 12, 565-575.
296. Kim, S. K.; Su, L. K.; Oh, Y.; Kemp, B. L.; Hong, W. K.; Mao, L. Alterations of PTEN/MMACI, A Candidate Tumor Suppressor Gene, and its Homologue, PTH2, in Small Cell Lung Cancer Cell Lines. Oncogene 1998, 16, 89-93.
297. Forgacs, E.; Biesterveld, E. J.; Sekido, Y.; Fong, K.; Muneer, S.; Wistuba, H.; Milchgrub, S.; Brezinschek, R.; Virmani, A.; Gazdar, A. F.; Minna, J. D. Mutation Analysis of the PTEN/MMACI Gene in Lung Cancer. Oncogene 1998, 17, 1557-1565.
298. Rena, G.; Guo, S.; Cichy, S. C.; Unterman, T. G.; Cohen, P. Phosphorylation of the Transcription Factor Forkhead Family Member FKHR by Protein Kinase B. J. Biol. Chem. 1999, 274, 17179-17183.
299. Guo, S.; Rena, G.; Cichy, S.; He, X.; Cohen, P.; Unterman, T. Phosphorylation of Serine 256 by Protein Kinase B Disrupts Transactivation by FKHR and Mediates Effects of Insulin on Insulin-like Growth Factor-binding Protein-1 Promoter Activity through a Conserved Insulin Response Sequence. J. Biol. Chem. 1999, 274, 17184-17192.
300. Zhou, B. P.; Liao, Y.; Xia, W.; Spohn, B.; Lee, M. H.; Hung, M. C. Cytoplasmic Localization of p21Cip1/WAF1 by Akt-induced Phosphorylation in HER-2/neu-overexpressing Cells. Nat. Cell Biol. 2001, 3, 245-252.
301. Lin, H. K.; Yeh, S.; Kang, H. Y.; Chang, C. Akt Suppresses Androgen-induced Apoptosis by Phosphorylating and inhibiting Androgen Receptor. Proc. Natl. Acad Sci. USA 2001, 98, 7200-7205.
302. Campbell, R. A.; Bhat-Nakshatri, P.; Patel, N. M.; Constantinidou, D.; Ali, S.; Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated Activation of Estrogen Receptor Alpha: A New Model for Anti-estrogen Resistance. J. Biol. Chem. 2001, 276, 9817-9824.
303. Du, K.; Montminy, M. CREB is a Regulatory Target for the Protein Kinase Akt/PKB. J. Biol. Chem. 1998, 273, 32377-32379.
304. Kang, S. S.; Kwon, T.; Kwon, D. Y.; Do, S. I. Akt Protein Kinase Enhances Human Telomerase Activity through Phosphorylation of Telomerase Reverse Transcriptase Subunit. J. Biol. Chem. 1999, 274, 13085-13090.